Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Baxter
UBS
Covington
Moodys
Daiichi Sankyo
Mallinckrodt
US Department of Justice
Cipla
McKesson

Generated: October 19, 2017

DrugPatentWatch Database Preview

COSOPT Drug Profile

« Back to Dashboard

What is the patent landscape for Cosopt, and when can generic versions of Cosopt launch?

Cosopt is a drug marketed by Oak Pharms Inc and is included in two NDAs.

The generic ingredient in COSOPT is dorzolamide hydrochloride; timolol maleate. There are fourteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the dorzolamide hydrochloride; timolol maleate profile page.

Summary for Tradename: COSOPT

US Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list2
Bulk Api Vendors: see list42
Clinical Trials: see list34
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:COSOPT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oak Pharms Inc
COSOPT
dorzolamide hydrochloride; timolol maleate
SOLUTION/DROPS;OPHTHALMIC020869-001Apr 7, 1998ATRXYesYes► Subscribe► Subscribe► Subscribe
Oak Pharms Inc
COSOPT PF
dorzolamide hydrochloride; timolol maleate
SOLUTION/DROPS;OPHTHALMIC202667-001Feb 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: COSOPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Oak Pharms Inc
COSOPT
dorzolamide hydrochloride; timolol maleate
SOLUTION/DROPS;OPHTHALMIC020869-001Apr 7, 1998► Subscribe► Subscribe
Oak Pharms Inc
COSOPT
dorzolamide hydrochloride; timolol maleate
SOLUTION/DROPS;OPHTHALMIC020869-001Apr 7, 1998► Subscribe► Subscribe
Oak Pharms Inc
COSOPT
dorzolamide hydrochloride; timolol maleate
SOLUTION/DROPS;OPHTHALMIC020869-001Apr 7, 1998► Subscribe► Subscribe
Oak Pharms Inc
COSOPT
dorzolamide hydrochloride; timolol maleate
SOLUTION/DROPS;OPHTHALMIC020869-001Apr 7, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for COSOPT

Drugname Dosage Strength RLD Submissiondate
dorzolamide hydrochloride and timolol maleateOphthalmic Solution2%/0.5%Cosopt10/11/2005
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Fish and Richardson
Chinese Patent Office
Moodys
US Department of Justice
Farmers Insurance
QuintilesIMS
Cantor Fitzgerald
Accenture
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot